Atara Biotherapeutics, Inc.

Despite the ongoing upheaval across the agency, the US Food and Drug Administration maintained its typical reliability when it came to meeting user fee goal dates in the first quarter of 2025, the Pi

Sutro Biopharma announced after the stock market closed on 13 March that as a result of a strategic portfolio review the company will end development of its one and only clinical-stage antibody drug c

“We’re at an exciting juncture in medicine where the perceived scientific boundaries in treatment across therapeutic areas continue to dissolve.” These words from Jeffrey Jones , chief medical office

Atara Biotherapeutics' hopes of getting Ebvallo approved soon in the US have been dashed after the Food and Drug Administration rejected the off-the-shelf cell therapy due to manufacturing issues, sen